Sellas Life Sciences has achieved the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to measure the drug's efficacy, with preliminary results projected this quarter. Analysts warn that prolonged trial durations may raise the likelihood of failure. The company continues to monitor the trial's progress closely, with updates anticipated as the trial progresses. The REGAL trial is a key step in the development of Galinpepimut-S, which has shown encouraging results in previous phases. Sellas Life Sciences remains focused on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's thoughtful approach to clinical trials and data analysis is strongly regarded in the industry, and investors are watching the trial's outcome with care.